1
=
-
Natera, Inc. Common Stock
As of May 18, 2026 at 24:05 UTC
Chart
About Natera, Inc. Common Stock
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Market Statistics
Trading Metrics
How to Buy NTRA
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy NTRA
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesWilliam Blair initiated coverage on Natera (NASDAQ: NTRA), highlighting the company's strong positioning in the minimal residual disease (MRD) testing market. Analyst Andrew Brackmann estimates Natera generated close to $1 billion in MRD revenue in 2025 with expected growth exceeding 40% in 2026. The MRD market, valued at over $20 billion, is still in early stages with mid- to high-single digit penetration. Natera's competitive advantages include early-mover status, clinical evidence, and strong market share in NIPT (over 50%), positioning it well against competitors as the market expands.
Natera announced promising results from a prospective study showing its Signatera molecular residual disease (MRD) test can identify older women with early-stage ER+/HER2- breast cancer who can be managed with primary endocrine therapy without surgery. The study of 43 women over 70 demonstrated 100% negative predictive value for MRD-negative patients and 100% longitudinal sensitivity for detecting progression. NTRA shares rose 5.26% to $196.68 on the news, with analysts maintaining a Buy rating and $248.06 average price target.
Exelixis, a U.S.-based biotech company specializing in cancer treatments, is positioned for market-beating returns through its growing pipeline beyond its blockbuster cabozantinib drug. The company reported 57.9% EPS growth in 2025 and recently received FDA approval for zanzalintinib for metastatic colorectal cancer. With zanzalintinib in four phase 3 trials and strategic partnerships with major pharma companies, Exelixis aims to become a top-five solid tumor oncology company.
Billionaire investor Stanley Druckenmiller holds two major positions in his portfolio: Natera (NTRA), a genetic testing company with strong revenue growth and expanding margins despite current losses, and Taiwan Semiconductor Manufacturing (TSM), which benefits from AI demand but faces challenges with rising capital expenditures that will limit future cash-flow margin expansion.
The global esoteric testing market is projected to grow from $27.52 billion in 2025 to $41.56 billion by 2031 at a 7.11% CAGR, driven by rising chronic disease rates, personalized medicine demand, and liquid biopsy adoption. However, stringent regulatory frameworks and reimbursement pressures pose significant challenges to market expansion.
